A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer
Principal Investigator
Mitchell Machtay, MD
Status
Closed to Accrual & Treatment
Date Opened To Accrual
November 05 2009
Date Closed to Accrual
March 27 2018
Disease Site
Head and Neck [HN]
Head and Neck
Phase
III
Developmental Therapeutics
No
Primary Objective
Test whether the addition of cetuximab to radiation therapy will improve overall survival (OS) in postoperative patients with intermediate risk following surgery
Protocol and Other Documents:
Available via the National Cancer Institute (NCI) Cancer Trials Support Unit (CTSU) website
Data Collection Notice:
Data for this trial is being collected via the NRG/RTOG Data Center.
Patient Population
Pathologically proven diagnosis of squamous cell carcinoma (including variants such as verrucous carcinoma, spindle cell carcinoma, carcinoma NOS, etc.) of the head/neck (oral cavity, oropharynx or larynx); clinical stage T2-T4a, N0-2, M0 or T1, N1-2, M0.
Target Accrual
700
Patient Study Webpage
There is no available patient study webpage available for this trial at this time.